Expert Interviews

Medical experts outline the current first-line treatment options for advanced non–clear cell RCC, including the factors influencing agent selection, as well as discuss how recent NCCN guideline updates and label changes affect treatment decisions in community practice.

Medical experts examine differences and similarities in the referral process and treatment protocols for non–BCMA-targeted vs BCMA-targeted bispecific therapies, including aspects like step-up dosing and premedication.

Medical experts address the referral process for bispecific therapy between community and academic centers, including patient eligibility and educational requirements such as REMS certification.

Hematologist-oncologists discuss GPRC5D-targeting treatments that are currently in development for patients with relapsed/refractory multiple myeloma.

Focusing on the MonumenTAL-1 study, Mary Steinbach, APRN, provides clinical insights on nail, skin, and oral toxicities associated with talquetamab.

Noopur Raje, MD, shares clinical perspectives on her experience treating patients with prior BCMA bispecific exposure and provides insights on adverse event management practices in patients receiving talquetamab.

Lisa Hwa, APRN, DNP, CNP, FAPO, describes the unique challenges in managing adverse events associated with GPRC5D therapy compared with other bispecifics.

The panel concludes its discussion with insights on challenges and unmet needs in the CML treatment landscape, highlighting ways to better support patients and caregivers.

CancerNetwork co-hosts Kristie L. Kahl and Andrew Svonavec highlight abstracts to look out for surrounding the multidisciplinary approach at the upcoming ESMO Congress in Barcelona, with some additional tidbits to round out the main event.

Experts explore additional toxicities observed with B-cell maturation antigen–targeting bispecifics, such as infections, neurotoxicity, and hematological issues, and discuss how these are managed in practice.

Experts explain the administration of step-up and treatment doses for GPRC5D at your institution, including whether they are given in clinic or in the community, and will discuss how patients are monitored for cytokine release syndrome and immune effector cell–associated neurotoxicity syndrome during the step-up phase.

Key opinion leaders share their impressions of the IMBrave150 trial data and discuss their real-world clinical experiences using atezolizumab plus bevacizumab in practice.

The panel presents the latest safety and efficacy updates from the IMbrave 150 trial.

Alessio Pigazzi, MD, PhD, FACS, FASCRS, provides advice for upcoming surgeons starting out in the colorectal cancer field.

Alessio Pigazzi, MD, PhD, FACS, FASCRS, discussed how robot-assisted surgery for colorectal cancers has evolved over the past 20 years.

Medical experts discuss streamlining referrals to reduce treatment delays, optimizing resources, comparing outcomes in collaborative vs noncollaborative settings, and managing patient reluctance about academic center referrals.v

Medical experts highlight the critical role of collaboration between academic and community physicians in managing multiple myeloma, focusing on coordinating care, maintaining communication, and ensuring centers are prepared for patient transitions.

Alessio Pigazzi, MD, PhD, FACS, FASCRS, discussed surgical and medical oncology developments in the colorectal cancer field.

Medical experts explore the main challenges in treating non–clear cell RCC compared with clear cell RCC, discussing how these difficulties vary between community and academic settings.

Medical experts give an overview of renal cell carcinoma (RCC), detailing the differences between clear cell and non–clear cell subtypes, the various forms of non–clear cell RCC, and the demographic and risk factor profiles associated with each subtype, while also discussing how histological differences influence prognosis.